No profile data available.
Ovid Therapeutics Inc. (OVID) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 23 full-time employees.
It reported revenue of $7.25 million for fiscal year 2025, up 1181.3% from fiscal year 2024, and net income of -$17.41 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $733,000, down 88.3% from a year before. Its market capitalization was $480.43 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
Ovid Therapeutics reported $7.25 million in revenue for fiscal year 2025, up 1181.3% from $566,000 in fiscal year 2024. In Q2 2026 revenue was $733,000.
$480.43 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Bright Minds Biosciences Inc. (DRUG), Regenxbio Inc. (RGNX), Neurogene Inc. (NGNE), Capricor Therapeutics, Inc. (CAPR).